Eli Lil­ly takes a one-two punch as Covid-19 an­ti­body com­bo study is halt­ed and man­u­fac­tur­ing ops fail in­spec­tion

An NIH tri­al for an Eli Lil­ly an­ti­body, one of two coro­n­avirus drugs Pres­i­dent Trump has tout­ed and urged the FDA to au­tho­rize in re­cent weeks, has been halt­ed over a safe­ty con­cern. And it is un­like­ly to start again for at least two weeks.

The study, known as AC­TIV-3, com­pared the Lil­ly an­ti­body plus remde­sivir to the an­ti­body plus place­bo in hos­pi­tal­ized Covid-19 pa­tients and was slat­ed to en­roll up to 10,000 vol­un­teers. In a state­ment re­leased late Tues­day, NI­AID said that they paused the study af­ter, in an ini­tial sam­ple of rough­ly 300 pa­tients, one group ap­peared to be do­ing bet­ter than the oth­er, al­though they did not spec­i­fy which group that was.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA